Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shin Nippon Biomedical Laboratories, Ltd. reported better-than-expected financial results for the first half of 2024, driven by strong performance in its domestic nonclinical CRO business and lower-than-expected expenses related to an NDA resubmission. The company’s revenue and profits significantly surpassed forecasts, with interim profit showing a remarkable 55.1% increase over projections.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.